Technology | Treatment Planning | October 24, 2018

Siris Medical Releases PlanMD Decision Support Software

New software introduces real-time prescriptive contouring to enable faster, smarter radiation therapy treatment planning and better outcomes

Siris Medical Releases PlanMD Decision Support Software

October 24, 2018 — Siris Medical Inc. announced the release of its new artificial intelligence (AI) treatment decision-support system for use in radiation oncology. The new PlanMD software enables radiation oncology clinical teams to leverage patient data and artificial intelligence to efficiently empower their treatment decisions. The software is the first and only tool, according to the company, that enables the physician to see the effect of editing contours in real time, without re-optimizing or replanning.

PlanMD complements Siris Medical’s QuickMatch software, which accelerates the treatment planning process by using AI to quickly identify the most similar cases previously treated to inform planning decisions and help reduce dose to critical structures. Siris Medical President and CEO Colin Carpenter, Ph.D., said the software has been shown to enable clinical teams to save up to 70 percent of the time required to plan treatment.

This announcement follows a recent publication, “Clinical decision support of radiotherapy treatment planning: A data-driven machine learning strategy for patient-specific dosimetric decision making,” in the Journal of Radiotherapy and Oncology in December 2017.1 This study demonstrates the ability of the QuickMatch software to draw upon historical clinical insights for patient-specific decision making. The study was a collaborative effort between the University of California San Francisco (UCSF), University of Pennsylvania, University of Maryland and Siris Medical.

For more information: www.siris-medical.com

Reference

1. Valdes G., Simone C.B., Chen J., et al. Clinical decision support of radiotherapy treatment planning: A data-driven machine learning strategy for patient-specific dosimetric decision making. Journal of Radiotherapy and Oncology, Nov. 20, 2017. https://doi.org/10.1016/j.radonc.2017.10.014

Related Content

Sponsored Content | Videos | Enterprise Imaging | February 19, 2020
Bill Lacy, vice president, Medical Informatics at FUJIFILM Medic...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
The Candelis ImageGrid Plus PACS Server is an ultra-high-performance platform that can support high volume healthcare environments of 1,000 plus modalities
News | PACS | February 12, 2020
February 12, 2020 — The Candelis ImageGrid Plus...
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
An example of artificial intelligence (AI) being developed by Hitachi to automatically review and identify nodules on lung CT scans. This is part of a suite of AI apps Hitachi is developing. This example was being shown as a work in progress at RSNA 2019.

An example of artificial intelligence (AI) being developed by Hitachi to automatically review and identify nodules on lung CT scans. This is part of a suite of AI apps Hitachi is developing. This example was being shown as a work in progress at RSNA 2019. Photo by Dave Fornell.

Feature | Artificial Intelligence | February 07, 2020 | Sanjay Parekh, Ph.D. 
February 7, 2020 – At the 2019 Radiological Society...